Is Tyra Biosciences, Inc. (TYRA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.3% / 30% | 18.3% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.3% / 33% | 18.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 1.7% / 33% | 93.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.3% / 33% | 18.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 1.7% / 33% | 93.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -39.8% | |
| Return on Assets (ROA) | -25.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$95M |
| Free Cash Flow | -$95M |
| Total Debt | $6M |
| Debt-to-Equity | 2.2 |
| Current Ratio | 14.7 |
| Total Assets | $283M |
Price & Trading
| Last Close | $38.03 |
| 50-Day MA | $32.92 |
| 200-Day MA | $19.67 |
| Avg Volume | 912K |
| Beta | 1.1 |
|
52-Week Range
$6.42
| |
About Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Tyra Biosciences, Inc. (TYRA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Tyra Biosciences, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Tyra Biosciences, Inc.'s debt ratio?
Tyra Biosciences, Inc.'s debt ratio is 0.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.7%.
What are Tyra Biosciences, Inc.'s key financial metrics?
Tyra Biosciences, Inc. has a market capitalization of $2.0B. Return on equity stands at -39.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.